CAMBRIDGE, Mass., Oct. 8, 2020 /PRNewswire/ — Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D., “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage life-sciences startups, today announced AXONIS Therapeutics, Inc. and Tenza as the winners of the Astellas-sponsored “Golden Ticket Competition”. A Golden Ticket award offers entrepreneurial scientists or emerging biotechnology startups one-year usage of LabCentral’s state-of-the-art lab facility in Cambridge, Massachusetts, as well as access to Astellas’ research and development (R&D) capabilities and business leaders.
AXONIS and Tenza were chosen for the strength of the innovation in their approach, the therapeutic potential of their research and alignment of their novel technological platforms with Astellas’ research and development (R&D) Focus Areas.
“In awarding these Golden Tickets, we are reinforcing Astellas’ ongoing commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide,” said Maruyama, President, AVM. “We applaud
Golden is announcing that it has raised $14.5 million in Series A funding. The round was led by previous investor Andreessen Horowitz, with the firm’s co-founder Marc Andreessen joining the startup’s board of directors.
When Golden launched last year, founder and CEO Jude Gomila told me that his goal was to create a knowledge base focused on areas where Wikipedia’s coverage is often spotty, particularly emerging technology and startups.
Gomila told me this week that “companies, technologies and the people involved in them” remain Golden’s strength. In that sense, you could see it as a competitor to Crunchbase, but with a much bigger emphasis on explaining and “clustering” information on big topics like quantum computing and COVID-19, rather than just aggregating key data about companies and people. (By the way, both TechCrunch and the author of this post have their own profile pages, though the latter is woefully empty.)
To celebrate the 20th anniversary of the Olympic Games Sydney 2000, the famous white exterior sails of the Sydney Opera House are becoming an enormous movie screen, showing Australian Catherine Freeman’s 400-metre gold medal win on 25 September 2000. She ran her final in 49.11 seconds, becoming the first Aboriginal athlete to win gold in an individual event at the Olympic Games.
The cinematic event celebrates not only Freeman’s historic achievement, but also its audiovisual preservation for future generations on an innovative, sustainable, long-term storage technology called “synthetic DNA”. This has been made possible thanks to a partnership between the Olympic Foundation for Culture and Heritage (OFCH) and the National Film and Sound Archive of Australia (NFSA).
The synthetic DNA project is a world first, and Freeman’s 400-metre gold medal win is the first Australian video to be encoded.
The master recording of the historic race has been
LAS VEGAS, NV / ACCESSWIRE / September 24, 2020 / Golden Triangle Ventures, Inc. (OTC PINK:TOMI) has made significant advances on its technology division under HyFrontier Technologies, Inc. The company is currently testing its HyGrO technology on many applications and plants. The company is pleased to announce the preliminary results on our CBD Hemp test with Colorado Hemp Services which is being grown with the HyGrO technology against a Control Test, now underway in Pueblo Colorado.
Travis Nelson, Principal of Colorado Hemp Services, states, “We are overly satisfied with the results we are seeing from watering our plants with HyFrontier Technologies’ HyGrO unit. We are approaching harvest soon and we are seeing a much larger flower set. We look forward to testing all the flowers at a certified testing facility to compare cannabinoid profiles after harvest. So far, the leaves on the HyGrO side of the test are greener and